

LDL-C Lowering Therapies: The Changing Lipid Landscape

MONDAY, JULY 27, 2020



Heart House
Roundtables



LDL-C Lowering Therapies: The Changing Lipid Landscape

Recently approved and emerging LDL-C lowering therapies represent exciting new opportunities for primary and secondary prevention of atherosclerotic cardiovascular disease (ASCVD), but also present new questions and challenges for the cardiovascular community.

The LDL-C Lowering Therapies: The Changing Lipid Landscape Roundtable will address critical issues that continue to challenge the ability of clinicians to provide optimal care for patients with dyslipidemia. The goal of this Roundtable is to understand and address the role of new and emerging LDL-C lowering therapies in patients with ASCVD and high-risk primary prevention as well as those with statin-associated side effects. We aim to identify barriers to adding these new non-statin therapies and implementation of therapies in patients with statin-associated side effects.

Interactive discussions will be used to inform the development of actionable content to be used at the point of care, which may include clinical policy, health policy statements or other clinician tools.

Heart House Roundtables

The Heart House Roundtables explore the practical issues that clinicians and patients face every day within high-value clinical areas. They gather a diverse group of experts representing a wide variety of professional societies relevant to a specific topic, as well as other key stakeholders such as patients, federal agencies, health plans, integrated health systems and others as identified. The diversity of expertise is critical to the success of the roundtables, which provide a valuable forum for interactive and facilitated discussions aimed at brainstorming practical solutions to help drive treatment decisions based on the latest evidence and expert opinion. These meetings are designed to optimize in-depth discussion among participants that not only identify and clarify the issues, but also allows participants the opportunity to brainstorm possible solutions to address those issues.

For more information, visit [ACC.org/HeartHouseRoundtables](https://www.acc.org/HeartHouseRoundtables).

LDL-C LOWERING THERAPIES: THE CHANGING LIPID LANDSCAPE

AGENDA

Monday, July 27, 2020

10:00 a.m.	WELCOME <i>Dipti Itchhaporia, MD, FACC; ACC Vice President</i>
10:05 a.m.	Overview of Roundtable and Introductions <i>Pamela B. Morris, MD, FACC, FAHA, FASPC, FNLA and Michael D. Shapiro, DO, MCR, FACC, FAHA; Chair and Vice-Chair</i>
10:20 a.m.	SESSION 1: LDL-C: NEW AND EMERGING THERAPIES FOR THE HIGH-RISK PATIENT <ul style="list-style-type: none">• Non-Statin Therapies for LDL-Cholesterol Lowering: Ezetimibe and Bempedoic Acid <i>Anne Carol Goldberg, MD, FACP, FAHA, FNLA</i>• What is New for Inhibition of PCSK9? <i>Christie M. Ballantyne, MD, FACC, FACP, FNLA</i>• Interactive Breakout Session (45 minutes)• Report Back to Full Group (35 minutes)
12:10 p.m.	BREAK
12:20 p.m.	SESSION 2: BARRIERS AND OPPORTUNITIES IN THE MANAGEMENT OF STATIN-ASSOCIATED SIDE EFFECTS (SASE) IN THE HIGH-RISK PATIENT <ul style="list-style-type: none">• Defining Statin Associated Adverse Events <i>Paul Thompson, MD, FACC</i>• Interactive Breakout Session (45 minutes)• Report Back to Full Group (35 minutes)
2:00 p.m.	Q&A AND RECAP SESSION (30 minutes) Address Questions from Webex Chat and Prioritize Next Steps <i>Pamela B. Morris, MD, FACC, FAHA, FASPC, FNLA and Michael D. Shapiro, DO, MCR, FACC, FAHA; Chair and Vice-Chair</i>
2:30 p.m.	ADJOURN

On behalf of the ACC, we are thankful to the members of the LDL-C Lowering Therapies: The Changing Lipid Landscape Roundtable Planning Committee for their hard work and guidance in planning and executing this virtual Roundtable.

ACC LDL-C LOWERING THERAPIES: THE CHANGING LIPID LANDSCAPE ROUNDTABLE PLANNING COMMITTEE



Pamela B. Morris, MD, FACC, FAHA, FASPC, FNLA (Chair)

Professor of Medicine
Director, Seinsheimer Cardiovascular Health Program
Co-Director, Women's Heart Care
Medical University of South Carolina




Michael D. Shapiro, DO, MCR, FACC, FAHA (Vice-Chair)

Professor of Cardiology and Molecular Medicine
Wake Forest University School of Medicine
Director, Center for Prevention of Cardiovascular Disease
Section on Cardiovascular Medicine
Wake Forest Baptist Medical Center



Christie M. Ballantyne, MD, FACC, FACP, FNLA

Professor of Medicine
Chief, Sections of Cardiology and Cardiovascular Research
Baylor College of Medicine
Director, Center for Cardiovascular Disease Prevention
Houston Methodist Hospital DeBakey Heart and Vascular Center



Pam R. Taub, MD, FACC, FASPC

Director of Step Family Foundation Cardiovascular Rehabilitation and Wellness Center
Associate Professor of Medicine
UC San Diego Health System
Division of Cardiovascular Medicine



Kim K. Birtcher, PharmD, MS, CDE, AACC, FNLA

Clinical Professor
University of Houston College of Pharmacy
Clinical Pharmacist
Kelsey-Seybold Clinic Cardiology Department



Salim S. Virani, MD, PhD, FACC, FAHA

Professor, Section of Cardiovascular Research
Director, Cardiovascular Disease Fellowship Training Program
Baylor College of Medicine
Staff Cardiologist, Michael E. DeBakey Veterans Affairs Medical Center



James Underberg, MD, MS, FACPM, FACP, FNYAM, FASPC, FNLA

Lipidology & Cardiovascular Disease Prevention
Clinical Assistant Professor of Medicine
NYU Medical School & NYU Center for CV Prevention
Director, Bellevue Hospital Lipid Clinic
Past-President, National Lipid Association

We are grateful to our supporters for their commitment to the LDL-C Lowering Therapies: The Changing Lipid Landscape Roundtable.

